MPP Strikes Deal For Long-Acting Injectable HIV Candidate
Monthly Subcutaneous Injection Licensed From University Of Washington Could Replace Daily Pills
Executive Summary
The University of Washington has agreed to license an in-development HIV treatment to the Medicines Patent Pool, which takes the form of a monthly subcutaneous injection instead of daily oral treatment.
You may also be interested in...
Strides CEO: US COMPETES Act Creates Quality Differentiator
The $1m-$10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan believes. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.
Strides CEO: US COMPETES Act Creates Quality Differentiator
The $1-10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan tells Scrip. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.
MPP And WHO Announce COVID Technology License Via C-TAP
The WHO and Medicines Patent Pool have announced “the first transparent, global, non-exclusive license for a COVID-19 technology” after striking a deal for a COVID-19 serological antibody technology with the Spanish National Research Council through the WHO’s COVID-19 Technology Access Pool.